Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP T Combined Vaccine (PENTAXIM) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.

Trial Profile

Immunogenicity and Safety of the Sanofi Pasteur DTacP-IPV//PRP T Combined Vaccine (PENTAXIM) Given as a Three-Dose Primary Vaccination at 6, 10, and 14 Weeks of Age and Followed by a Booster Dose at 18-19 Months of Age in Healthy Infants in India.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2010

At a glance

  • Drugs Hib-DTaP-poliovirus vaccine (Primary)
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Feb 2010 Official Title amended as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
    • 16 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top